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Abstract
Background: FADD (Fas-associated death domain) adaptor is a crucial protein involved in the induction of cell
death but also mediates non-apoptotic actions via a phosphorylated form (p-Ser194-FADD). This study investigated
the possible association of FADD forms with age-related neuropathologies, cognitive function, and the odds of
dementia in an elderly community sample.
Methods: FADD forms were quantified by western blot analysis in dorsolateral prefrontal cortex (DLPFC) samples
from a large cohort of participants in a community-based aging study (Memory and Aging Project, MAP),
experiencing no-(NCI, n = 51) or mild-(MCI, n = 42) cognitive impairment, or dementia (n = 57).
Results: Cortical FADD was lower in subjects with dementia and lower FADD was associated with a greater load of
amyloid-β pathology, fewer presynaptic terminal markers, poorer cognitive function and increased odds of dementia.
Together with the observations of FADD redistribution into tangles and dystrophic neurites within plaques in
Alzheimer’s disease brains, and its reduction in APP23 mouse cortex, the results suggest this multifunctional protein
might participate in the mechanisms linking amyloid and tau pathologies during the course of the illness.
Conclusions: The present data suggests FADD as a putative biomarker for pathological processes associated with the
course of clinical dementia.
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Background
Aging is a relevant risk factor for Alzheimer’s disease
(AD) [1], which is the main cause of dementia and is
characterized by deposition of amyloid β in neuritic pla-
ques, accumulation of tau in intracellular neurofibrillary
tangles, and neuronal loss (see review in [2]). Cognitive
decline is a prerequisite for the clinical diagnosis of
dementia associated with AD, and usually correlates
better with neurofibrillary tangles of hyperphosphorylated
tau than with amyloid β plaques (reviewed in [3, 4]).
Although nearly all brains in old age contain some patho-
logical signs of AD, only some individuals develop the
disease [5–9], which seems to be greatly influenced by dif-
ferences in cognitive reserve [10–12]. This premise,
together with the time-course of the pathophysiology of
the disease (i.e., preclinical stage initiated 15–20 years
prior to emergence of clinical signs; [4]) suggests that
these pathological markers may not be sufficient or
necessary to initiate cognitive decline in humans. Conse-
quently, the identification of new biomarkers for diagnosis
and for a sensitive assessment of the progression of AD
(i.e., cognitive decline) is an important area of current
research.
In line with this, cell death mediated via apoptosis has
been thought to be one of the possible underlying
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mechanisms of neuronal cell loss in AD (see review in
[13]). In fact, several studies have been performed in post-
mortem brain tissue from AD patients on some of the
cellular components of the apoptotic pathway [13]. For
example, the expression of some components of the
extrinsic pathway, like the cell death receptor Fas (e.g.,
[14–16]), its ligand Fas-L [17] and some effector caspases
[18, 19] showed evidence of apoptosis (i.e., DNA fragmen-
tation determined by TUNEL method, [18]) in the brains
of AD patients. However, several contradictory results
have also been described, suggesting that the apoptotic
mechanism of neuronal death in AD might be infrequent
or undetectable (e.g., [20, 21]), and that in fact, even cell
survival mechanisms might take place as an adaptive
response to a prior insult (see revision in [13]).
In terms of cell fate regulation (i.e., balance between
cell death and survival), a key adaptor molecule of the
apoptotic Fas receptor [22], the FADD (Fas-associated
death domain) is a crucial protein involved in the induc-
tion of cell death but also able to mediate non-apoptotic
actions (cell survival, differentiation and neuroplasticity)
via a phosphorylated form (p-Ser194-FADD) and its
nuclear localization [23, 24]. Multifunctional FADD
works in vivo as a common and major signaling step in
the initial activation of structurally different receptors
(e.g. neurotransmitter G protein-coupled receptors and
receptor channels; see [25–27]). Although FADD has a
crucial role during embryogenesis/development [28], lit-
tle is known about its expression or functions as the
brain ages [29] and in age-related neurophatologies. In
AD one prior study showed that although FADD signal-
ing pathway was triggered within the basal forebrain
cholinergic neurons, as FADD-positive tangle-like struc-
tures were localized in neurons, there was no apoptotic
cell death as measured by DNA fragmentation [30].
Another study showed that the induction of neural
apoptosis produced by amyloid β in hippocampal neuron
cultures was mediated via FADD and caspase-8 activity
[31]. However, none of these studies explored the
potential link between brain FADD (or other apoptotic
markers) variations and cognitive decline or AD-related
pathology.
Against this background, this study investigated the
possible associations of FADD forms (i.e., speculated in-
crease of pro-apoptotic FADD) with the presence and
severity of multiple age-related neuropathologies, as well
as with cognitive function and the risk of clinical demen-
tia in an elderly large community sample. Cortical
expression of FADD forms (i.e., pro-apoptotic FADD
and anti-apoptotic p-FADD) were measured in postmor-
tem tissue samples from a large cohort of community-
dwelling participants of the Memory and Aging Project
(MAP) [32], with or without clinical diagnosis of demen-
tia, and representative of the broad range of cognitive
impairment in the overall elderly, aging population.
Moreover, to further ascertain the possible role of FADD
regulation in AD, we utilized APP23 transgenic mice,
which overexpress mutant human amyloid precursor
protein (APP) and develop brain amyloid β deposits
in brain progressively with age [33]. A preliminary
report of a portion of this work was presented at the
55th Annual Meeting of the American College of
Neuropsychopharmacology [34].
Methods
Selection of MAP participants: cognitive and
neuropathological evaluations
The Memory and Aging Project (MAP) recruits elderly
volunteers (more than 1,800 since 1997) without known
dementia at enrollment, living in the metropolitan area
of Chicago (IL, USA) [9, 32]. All participants signed an
informed consent and an Anatomic Gift Act for organ
donation upon death. The Institutional Review Board of
Rush University Medical Center approved this study.
The overall follow-up rate was 95% and the autopsy rate
exceeded 80% resulting in more than 650 autopsies. A
large number of MAP participants (n = 426) from con-
secutive autopsies were used in a recent study (see [35]).
From those, n = 150 participants were pseudorandomly
selected using a random sampling tool in JMP software
(version 12.1; SAS Institute, NC, USA), and included in
the present study. See Table 1 for a summary of their
demographic, cognitive (no cognitive impairment, NCI;
mild cognitive impairment, MCI; clinical dementia) and
pathological characteristics. Apolipoprotein E (APOE)
genotyping was performed with PCR assays by Agen-
court (Beckman Coulter Genomics, Brea, CA, USA).
Prior reports extensively reported the methodological
approaches to perform systematic cognitive, clinical and
neuropathological evaluations [9, 36]. Annual cognitive
evaluations included a series of 21 standard tests, 19 of
which were used for summary measures of episodic,
semantic and working memory, perceptual speed, and
visuospatial ability, and finally summarized into one
single variable to derive a global cognitive function score
[9, 37]. The mini mental state examination (MMSE) is
also reported for comparison to other studies (see
Table 1). A board-certified neuropsychologist blind to all
pathological data reviewed test results and rated the level
of cognitive impairment. A study clinician evaluated each
participant and diagnosed dementia and AD following the
National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association criteria [38] implemented
as described [39]. Cognitive impairment not meeting the
criteria for dementia was diagnosed as mild cognitive im-
pairment (MCI) as described [40]. NCI refers to those
without MCI or dementia [41].
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The pathological examinations were made by a board-
certified neuropathologist, blind to all clinical data. AD
pathology (i.e. plaques and tangles) was evaluated in
formalin-fixed, paraffin-embedded sections from
multiple key brain regions in the frontal, temporal,
parietal, and occipital lobes, as previously described [42],
although only data from the dorsolateral prefrontal cor-
tex (DLPFC) was used for statistical modeling, unless
otherwise specified. Briefly, sections from all subjects
and brain areas were assessed using both a modified
Bielschowsky silver staining for counts of diffuse and
neuritic plaques, and neurofibrillary tangle (NFTs), as
described [43]. Immunocytochemistry with amyloid-β
(clones 10D5 or 4G8) to quantify the percent area occu-
pied by amyloid-β by image analysis, and phosphotau
(clone AT8) antibodies – to quantify the density of tau
tangles by stereology [42]. The severity and/or stage of
AD in each participant was later addressed following the
National Institute on Aging (NIA)-Reagan criteria, which
incorporates the Consortium to Establish a Registry of
Alzheimer’s Disease (CERAD) scale [44], and Braak
staging [45]. Other neuropathologies, including cerebro-
vascular diseases (macroscopic and microscopic infarcts,
arteriolosclerosis and atherosclerosis), Lewy bodies, and
hippocampal sclerosis, were also examined as described
elsewhere [9, 36]. Stereological approaches to account
for resting, activated or total microglial cells in the
DLPFC were detailed earlier [46].
Animals
APP23 transgenic mice, overexpressing a variant of
human APP carrying the ‘Swedish double mutation’
KM670/671NL [33], and wild-type (WT) littermates
were provided by Novartis Pharma (Basel, Switzerland)
at different ages (3, 12 and 22 months old; n = 5–6 per
genotype and age). Mice were killed by decapitation, and
the frontal cortex was dissected and prepared for further
Western blot (WB) analysis [47].
Tissue collection, immunoassays and quantification of
target proteins
At the time of autopsy of MAP participants, tissue slabs
from the middle-frontal gyrus (Brodmann’s area 46/9) of
the DLPFC were dissected following a standard human
brain atlas [48], and stored at −80 °C. The DLPFC was
selected for its central role in complex cognitive tasks
and contribution to age-related cognitive decline [49].
For further immunoassays, grey matter tissue was care-
fully sampled from each of the slabs avoiding thawing.
Total homogenates from DLPFC samples (40–80 mg)
were prepared in ice-cold PBS pH 7.4 following usual
procedures [11]. Then, protein concentrations were
Table 1 Demographic, cognitive and pathological characteristicsa of MAP participants included in the present study
Variable All participants (n = 150) NCI (n = 51) MCI (n = 42) Dementia (n = 57)
Demographic
Female, no. (%) 105 (70%) 40 (78%) 27 (64%) 38 (67%)
Age at death, years 88.7 ± 6.3 86.7 ± 6.7 88.1 ± 6.8 90.9 ± 4.7
Education, years 14.6 ± 2.9 13.9 ± 2.5 15.0 ± 2.8 15.0 ± 3.3
Race, no. W:AA 146:4 49:2 41:1 56:1
APOE ε4 carrier, no. (%) 33 (22%) 7 (14%) 11 (26%) 15 (26%)
PMI, hours 6.6 ± 3.8 6.2 ± 2.1 7.6 ± 5.6 6.2 ± 3.1
Cognitive function proximate to death
Global cognition score −0.77 ± 1.01 0.10 ± 0.39 −0.47 ± 0.43 −1.80 ± 0.78
MMSE 21.9 ± 8.2 27.7 ± 1.9 24.9 ± 4.6 14.4 ± 8.1
Pathological
Macroinfarcts, no (%)b 45 (30%) 10 (20%) 15 (36%) 20 (35%)
Lewy bodies, no (%)b 25 (17%) 4 (8%) 1 (2%) 20 (35%)
Hippocampal sclerosis, no (%)b 14 (9%) 0 (0%) 4 (10%) 10 (18%)
Arteriolosclerosisb 1.39 ± 0.87 1.24 ± 0.84 1.38 ± 0.82 1.53 ± 0.93
Amyloid plaquesc 5.3 ± 5.9 2.9 ± 3.3 5.5 ± 6.5 7.3 ± 6.5
Tanglesc 1.1 ± 3.0 0.4 ± 1.7 1.1 ± 3.0 1.8 ± 3.7
Abbreviations: AA Afro-American, AD Alzheimer’s disease, MAP Memory and Aging Project, MCI mild cognitive impairment, MMSE mini mental state examination,
NCI, no cognitive impairment, PMI postmortem interval, SD standard deviation, W White
aValues are mean ± SD unless noted otherwise
bGlobal values
cValues obtained in the contralateral dorsolateral prefrontal cortex (DLPFC) by immunohistochemistry with specific antibodies
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determined by DC assay (Bio-Rad, Hercules, CA, USA)
and samples were adjusted to equal concentrations with
homogenization buffer. A greater amount of a reference
MAP cortical sample (~1 g) was homogenized and
prepared following the same conditions to be used as an
internal control (i.e., standard sample) in the immuno-
blot assays.
Cortical samples from MAP participants (40 μg) or
APP23/WT mice (10 μg) were resolved by electrophor-
esis on 10% SDS–PAGE minigels (Bio-Rad Laboratories,
Hercules, CA, USA). Every gel was run with 14 brain
samples, including 11 MAP participants (or 11 APP23/
WT mice samples) selected randomly, and the triplicate
standard samples (the reference MAP sample or a pool
of WT mice) space-loaded across the gel, and a molecu-
lar weight ladder (Bio-Rad). Each cortical sample was
assessed at least three times in different gels (i.e., with
randomly allocated brain samples) on different days.
Following electrophoretic separation, proteins were
transferred to nitrocellulose membranes, then incubated
overnight at 4 °C in blocking solution with anti-FADD
(H-181) (1:5000; Santa Cruz Biotechnology, CA, USA)
(see [50, 51] for labeling in post-mortem human brain
tissue). The secondary antibody was incubated for 1 h at
room temperature (1:5000 dilution; Cell Signaling).
Immunoreactivity of target proteins was detected with
ECL reagents (Amersham, Buckinghamshire, UK) and
signal of bound antibody was visualized by exposure to
autoradiographic film (Amersham ECL Hyperfilm) for 1
to 60 min, then quantified by densitometric scanning
(GS-800 Imaging Calibrated Densitometer, Bio-Rad).
Quantification of p-FADD and ß-actin protein contents
were performed by sequentially stripping and reprobing
all membranes, first for anti-phospho-Ser194 FADD
(1:1000; Santa Cruz Biotechnology, CA, USA), and then
for anti-ß-actin (clone AC-15) (1:10000; Sigma-Aldrich,
MO, USA). For each sample, immunoreactivity of FADD
or p-FADD was first divided by that of ß-actin (i.e., pro-
tein content data normalization) within the same gel,
and then calculated as a percentage of in-gel standards.
The mean value for each sample from at least three
separate gels was used as a final estimate. During the
above procedures, the experimenter was blind to the
demographic, cognitive and pathological characteristics
of MAP participants.
Quantification of the presynaptic proteins syntaxin-1,
synaptosomal-associated protein of 25 kDa (SNAP25),
vesicle-associated membrane protein (VAMP) and
syntaxin-binding protein-1 (STXBP1) was performed
previously by either enzyme-linked immunosorbent
assay [11] or Western blotting [35], in the same brain
samples. The DLPFC or overall brain immunodensities
of the three SNARE proteins (i.e. syntaxin-1, SNAP25,
VAMP) were z-scored and averaged to obtain a variable
accounting for cortical or global synapse density, directly
related to synaptopathy [52].
Immunofluorescence analysis
In an attempt to better characterize the potential
relationship between FADD (i.e., cellular and anatomical
localization), cognitive decline and AD pathology, 6
MAP subjects (3 pathology-free NCI subjects and 3
dementia cases with confirmed cortical AD pathology)
were selected for further immunofluorescence analysis.
Tissue blocks from the DLPFC (BA9) were cut coronally
with a vibrating microtome (Leica, Nussloch, Germany)
to a thickness of 40 μm, and floating sections were cryo-
preserved in solution at −20 °C until further use.
Antigen retrieval was done in 20 mM citrate buffer
(pH 6.0, 80 °C, 20 min) and was followed by blocking
sections and overnight incubation at 4 °C with one of
the following primary antibodies: anti-FADD (H-181,
Santa Cruz, 1:50), anti-NeuN (clone A60) (1:250; Chemi-
con, CA, USA), anti-syntaxin-1 (clone SP7) (1:1000;
[53]), anti-amyloid β (clone 6 F/3D) (1:100; Dako,
Glostrup, Denmark), anti-mis-folded pathologic tau
(clone Alz-50) (1:500; [54]). The next day, sections were
incubated with Alexa Fluor® 488-, 555- or 647-conju-
gated anti-mouse or anti-rabbit secondary antibodies
(1:500; Southern Biotech, AL, USA). Auto-fluorescence
was eliminated by incubation in 0.1% Sudan Black B and
70% ethanol solution for 15 min. Sections were mounted
in gelatin-coated slides and protected with an anti-fade
mounting reagent. A series of orthogonal images were
captured at a resolution of 1024×1024 pixels using a
LSM 5 Pascal confocal microscope (Zeiss; Jena,
Germany) and were visualized using a 63x/1.2 N.A.
water-immersion objective. Co-staining of FADD with
NeuN and syntaxin-1 was assessed to determine pres-
ence in neurons and/or synapses, while co-staining of
FADD with amyloid β or mis-folded pathologic tau
determined its presence within plaques and/or tangles,
respectively.
Statistical analyses
Data were analyzed and plotted with GraphPad Prism,
Version 6 (GraphPad Software, CA, USA) and/or JMP.
The level of significance was p ≤ 0.05. Initial compari-
sons of the cortical pathologic burden between clinically
diagnosed groups were done by Kruskal-Wallis followed
by Dunn’s test. Following WB assays, FADD and
p-FADD immunodensities were normalized to corre-
sponding β-actin values, and calculated as a percentage
of in-gel standards (see [35]). While these values were
used for plots, later statistical modeling procedures re-
quired a logarithmic transformation and standardization
in order to obtain normally distributed measures, as
confirmed by Shapiro-Wilk test. Multivariate analyses
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were performed to detect potentially confounding fac-
tors (e.g. demographic variables, APOE genotype,
tobacco or alcohol consumption, psychotropic drug pre-
scription, etc.) influencing cortical FADD/p-FADD
levels, as well as other interesting associations of these
molecules with multiple clinical, pathologic or neuro-
chemical variables measured along the study. Among
the confounding factors, only postmortem interval
(PMI) significantly correlated with FADD (r = −0.278; p
< 0.001) and p-FADD (r = 0.240; p < 0.003) brain values,
and therefore was included as a covariate (among other
variables) in all follow-up models. Differences in FADD
and p-FADD immunodensities between clinically diag-
nosed (i.e., NCI, MCI, dementia) or pathologically
graded (i.e. CERAD scaled or Braak staged) groups were
assessed by analysis of covariance (ANCOVA), control-
ling for sex, age, years of education and PMI, followed
by Tukey’s HSD test. Given the potential effects of cor-
tical FADD levels on cognitive performance, logistic or
linear regression models (controlled for sex, age, educa-
tion, PMI, and APOE genotype) were evaluated with
clinical dementia or cognitive function proximal to death
as respective outcomes, and pathological and neuro-
chemical variables as predictors (see [35]). Additionally,
we constructed univariate random-effects models,
controlled for demographics and neuropathologies as
above, to study the potential influence of FADD cortical
immunodensites (measured postmortem) on the cogni-
tive decline rates of MAP participants, as previously
described [12]. Note that these models assume fixed
values of cortical FADD levels longitudinally, a limitation
that must be considered when interpreting the results.
For WB experiments involving transgenic mice, data
was analyzed with two-way ANOVA, in which genotype
(WT vs. APP23) and age (3, 12 and 22 months old) were
treated as independent variables, followed by multiple
t-tests for two-group comparisons at each age.
ImageJ 2.0 (NIH, MA, USA) was used to determine
and quantify the extent of colocalization between two
immunofluorescent dyes in confocal imaging using an
unbiased built-in method [55, 56].
Results
Characteristics of MAP participants
Descriptive statistics for demographic, cognitive and
pathological characteristics of MAP participants are
summarized in Table 1. Out of the total of 150 MAP
participants, 51 subjects presented no cognitive impair-
ment (NCI), 42 displayed mild cognitive impairment
(MCI), while 57 were clinically diagnosed with dementia
(see Table 1, cognitive function proximate to death). As
expected, common AD disease pathology (i.e. amyloid-β
load and tau tangle density) in the DLPFC was more
abundant in dementia cases, as compared to NCI
participants (2.5–5.1 fold, p < 0.001) (see Fig. 1). None of
these markers could separate MCI from NCI
participants, while dementia cases showed greater dens-
ity of phosphotau tangles than MCI participants (1.6
fold, p = 0.003) (Fig. 1b). Notably, and as previously
reported in larger epidemiologic studies [7, 9] there is
ample variability in all clinically diagnosed groups.
Fig. 1 Measures of Alzheimer’s disease pathology in the DLPFC of
MAP participants in relation to their clinical diagnoses. Following
standard immunohistochemical assays with antibodies against (a)
amyloid β (clones 10D5 or 4G8) and (b) phosphotau (clone AT8), the
acquired images were thresholded and the percent area
immunostained was estimated for each participant and plotted by
clinical diagnosis criteria into no cognitive impairment (NCI, n = 51),
mild-cognitive impairment (NCI, n = 42) or dementia (DEM, n = 57).
Whiskers represent 10th and 90th percentiles and boxes enclose
interquartile ranges crossed by the median of AD pathology scores
within groups. Differences among groups were assessed by
Kruskal-Wallis followed by Dunn’s multiple comparison test. **p < 0.01
and ***p < 0.001
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Association of cortical FADD with common age-related
pathology
The total amounts of FADD protein forms (FADD and
p-FADD) were quantified in the DLPFC of MAP partici-
pants and normalized by β–actin protein content. Our
research group, which has been working with these spe-
cific antibodies for over a decade, characterized FADD
and p-FADD specific bands with several antibodies and
enzymatic dephosphorylation assays in brain tissue [50,
51, 57, 58] (see detailed revisions on these antibodies
characterization in [59, 60]). As reviewed in [60], and
shown in the present results, total FADD is mainly
immunodetected as a 51-kDa dimeric form, while p-
FADD is immunodetected as a 116-kDa oligomeric form
both in rodent and human brains. The results revealed
large variability among MAP participants for FADD
immunodensities (interquartile range = 20–83%), and
p-FADD (57–102%) as compared to that of β-actin
(93–105%).
Protein expression levels of FADD species did not
differ in the DLPFC of MAP participants displaying
cerebrovascular diseases (including infarcts), Lewy bod-
ies, cortical atrophy, or hippocampal sclerosis from those
who did not (data not shown). By contrast, FADD levels
(but not those of p-FADD) negatively correlated with
cortical amyloid-β load (r = −0.197; p = 0.038), without
apparent association with phosphotau density (r =
−0.124; p = 0.118) (Fig. 2). The association between
FADD and plaque pathology was stronger when using
neuritic (r = −0.266; p < 0.001) and diffuse (r = −0.258; p
= 0.006) plaque counts on the silver-stained sections,
rather than amyloid-β immunodensities, which are more
sensitive (Fig. 2). Consequently, subjects graded with
definite AD pathology by CERAD had lower cortical
FADD (but not p-FADD) immunodensities (−45%, p =
0.004) compared to plaque pathology-free participants
(Fig. 3a). These differences in FADD contents were not
found in association with Braak stage (Fig. 3b). Of note,
the above neuropathological assessments were part of
previous studies, where detailed information on image
processing and quantitative approaches was reported
[36, 41–43].
Additionally, greater FADD cortical immunodensity was
associated with lower number of activated (r = −0.224; p =
0.018, n = 110), but not resting or total, microglial cells
(Fig. 2), as characterized and quantified previously [46].
Confocal microscopy studies labeling FADD and HLA-
DR-positive (activated) microglia revealed significant colo-
calization between both markers within microglial pro-
cesses, but not in their nuclei (Additional file 1: Figure
S1). This type of overlap might be attributed to the engulf-
ment of neuronal-derived apoptotic material, and there-
fore activated microglia might mediate pro-apoptotic
FADD clearance. By contrast, higher FADD
immunodendities, but not p-FADD, were strongly associ-
ated with greater amounts of most presynaptic markers
quantified in the same cortical samples in prior studies
[11, 35], including syntaxin-1 (r = 0.274; p = 0.004), synap-
tosomal-associated protein of 25 kDa (SNAP-25; r= 0.290;
p= 0.002), vesicle-associated membrane protein (VAMP; r=
0.327; p < 0.001), and syntaxin-binding protein-1 (STXBP1; r
= 0.520; p < 0.001) (Fig. 2). Of note, loss of these markers is
related to synaptic pathology in aging and AD [61]. An
index of synapse density was estimated by averaging
syntaxin-1, SNAP-25 and VAMP immunodensities (i.e.,
the so-called SNARE proteins) in order to obtain a vari-
able accounting for cortical synaptopathy in MAP par-
ticipants in later statistical models. As expected, this
index also correlated with FADD values (r = 0.312; p <
0.001).
Association of cortical FADD with clinical dementia and
cognitive function
Comparing MAP participants by clinical diagnoses
revealed that FADD was lower in the DLPFC of subjects
with dementia relative to NCI (−42%, p = 0.003) and
MCI (−27%, p = 0.006), while p-FADD was not different
(Fig. 3c,d). Given these associations, we addressed the
hypothesis that lower cortical FADD levels may contrib-
ute to increased likelihood of dementia and/or greater
Fig. 2 Heatmap of Pearson’s r- (bottom-left) and P- (top-right) values
following multiple pairwise correlations between the pathologic,
stereological and neurochemical variables indicated. Abbreviations:
Aβ, amyloid β; AD, Alzheimer’s disease; DP, diffuse plaques; NFT,
neurofibrillary tangles; NP, neuritic plaques; p-, phospho-; SNAP25,
synaptosomal-associated protein of 25 kDa; STX1, syntaxin-1; STXBP1,
syntaxin-binding protein-1; Syn dens, synaptic density; VAMP,
vesicle-associated membrane protein
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cognitive impairment, either by mediating the effects of
age-related neuropathologies or independent of these in-
dices. We therefore performed a series of logistic and
linear regression models taking into account demo-
graphics, multiple age-related pathologies (i.e., amyloid
plaques, tangles, Lewy bodies, cerebrovascular diseases,
hippocampal sclerosis), and overall synaptic density,
omitting or including cortical FADD levels in the models
(see Table 2 and data not shown).
As expected, age and the presence of Lewy bodies
were associated with both higher odds of dementia and
poorer cognitive performance prior to death. Surpris-
ingly, in the present MAP subset, cerebrovascular
diseases and hippocampal sclerosis were related with
neither dementia nor cognitive function. However, in
previous studies using a much larger MAP sample, these
latter associations were indeed observed (see e.g. [12]).
Interestingly, the effect of DLPFC amyloid-β load on the
likelihood of dementia, which was marginally significant
when the FADD data was not included in the model
(data not shown), was not significant after addition of
FADD suggesting a mediation effect. Thus, participants
with lower FADD cortical density displayed a signifi-
cantly greater likelihood of dementia (odds ratio = 0.433,
p = 0.002). For example, a MAP participant with average
demographic and pathologic characteristics had a 2.5
fold-higher likelihood of dementia if the cortical density
of FADD is in the lower quartile versus the higher quar-
tile. Likewise, higher FADD levels in the DLPFC were
associated with better global cognitive function in MAP
Fig. 3 Regulation of FADD (upper plots) and p-FADD (bottom plots) protein forms in the DLPFC of MAP participants ranked either by: a CERAD
severity scale according to plaque pathology, and displaying no (4, n = 40), sparse (3, n = 26), moderate (2, n = 42), or frequent (1, n = 42) plaque
load; b Braak staging according to the spread of the tauopathy, and displaying no or transentorhinal deposition (0–II, n = 26), limbic spread (III–IV,
n = 92), or neocortical spread (V–VI, n = 32); or (c) clinical diagnoses with no cognitive impairment (NCI, n = 51), mild-cognitive impairment (NCI,
n = 42) or dementia (DEM, n = 57). Whiskers represent 10th and 90th percentiles of FADD or p-FADD values (normalized by β-actin protein
content), with boxed interquartile ranges crossed by the median for each experimental group and expressed as percentage of an in-gel-standard.
Differences among groups were assessed (after log-transformation and standardization of the datasets) by ANCOVA controlling for age, sex,
education and PMI followed by Tukey’s HSD post hoc test. **p < 0.01. d Representative immunoblots of FADD, p-FADD and β-actin, with various
participants and standard (ST) samples. The molecular masses of the various proteins are indicated in kDa. Full gel images are included in
Additional file 2: Figure S2
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participants (β = 0.499, p = 0.008), while the DLPFC load
of amyloid-β showed a marginal but significant effect on
cognitive function (β = −0.119, p = 0.046) after adding
FADD to the linear regression model. Cortical FADD
immunodensity did not mediate the large effects of the
DLPFC tauopathy on cognitive function; and surpris-
ingly had no impact on the risk of clinical dementia in
the current MAP sample (Table 2). Importantly, after
controlling for the demographic and pathologic indices
in Table 2, variations in DLPFC FADD immunodensity
explained 3.44% of the total variance in cognition among
MAP participants. Of note, the associations between the
clinical outcomes and the DLPFC pathologic and neuro-
chemical variables reported in Table 2 were very similar
to those observed when using the overall brain measure-
ments of amyloid and tau pathologies (data not shown).
Given that clinical diagnoses were not performed lon-
gitudinally, diagnoses of NCI/MCI/dementia were based
on cognitive evaluations nearest death. Therefore, estab-
lishing an association between the present neurochem-
ical data and the duration of the illness was not possible.
Because the onset of cognitive decline was somewhat
variable (see left panel in the Fig. 4), we performed
random-effects models to evaluate the potential associ-
ation between longitudinally ascertained cognitive
decline rates and postmortem cortical immunodensities
of FADD, adjusting for demographics and neuropathol-
ogies. Although a trend of faster cognitive decline rate
was observed for those subjects within the lower tertile
of FADD cortical values (see Fig. 4), in the statistical
approaches using univariate random-effects models
(controlling for all above confounders and pathologies)
this neurochemical variable only showed a marginal,
non-significant association with the annually evaluated
cognitive function (β = 0.266, p = 0.080), possibly because
the current sample size is underpowered for this type of
analysis.
Differences in FADD cortical distribution in clinical
dementia
In DLPFC sections from subjects (n = 3) with no cogni-
tive impairment (NCI) and free from age-related neuro-
pathology, most FADD intensity appeared in the
neuronal cell body, especially within nuclei (see merge
FADD-NeuN), and neuropil (synapses) (see Fig. 5a). In
particular, about 65% of FADD signal intensity was colo-
calized with NeuN, while 4% of FADD signal intensity
was colocalized with syntaxin-1. By contrast, in samples
from MAP participants with definite AD (e.g. AD1 and
AD2 subjects in Fig. 5a), there was no obvious colocali-
zation between FADD and NeuN labelings in neuronal
bodies. Interestingly, FADD appeared to accumulate in
Table 2 Regression models showing the associations of FADD levels in the DLPFC of MAP participants (and relevant covariates)
with clinical dementia and cognitive function
Clinical dementiaa Cognitive functionb
Model terms Odds ratio 95% CI P-value Estimate SD P-value
Age at death 1.104 1.025–1.197 0.0117* −0.0293 0.0118 0.0144*
Sex 1.231 0.440-3.433 0.6887 0.0856 0.0818 0.2976
Education years 1.133 0.966–1.339 0.1319 −0.0278 0.0260 0.2877
PMI 0.928 0.804–1.039 0.2401 −0.0052 0.0203 0.7991
APOE ε4 allele 0.752 0.235–2.267 0.6195 0.0369 0.0921 0.6892
Macroinfarctsc 1.295 0.498–3.328 0.5913 −0.1040 0.1616 0.5208
Lewy bodiesc 9.190 2.833–35.790 0.0005* −0.5993 0.1971 0.0028*
Hipp. sclerosis 3.935 0.832–21.845 0.0930 −0.1160 0.2813 0.6808
Arteriolosclerosisc 1.271 0.783–2.090 0.3350 −0.1022 0.0824 0.2166
Amyloid plaquesd 1.366 0.974–1.948 0.0756 −0.1186 0.0588 0.0458*
Tanglesd 1.040 0.906–1.208 0.5865 −0.0887 0.0265 0.0011*
Synaptic densitye 1.798 0.895–3.891 0.1151 −0.1003 0.1065 0.3475
FADDf 0.433 0.248–0.717 0.0019* 0.4993 0.1840 0.0075*
Abbreviations: C.I. confidence intervals, DLPFC dorsolateral prefrontal cortex, FADD Fas-associated protein with death domain, Hipp., hippocampal, MAP Memory
and Aging Project, MCI mild cognitive impairment, NCI no cognitive impairment, PMI postmortem interval, S.D., standard deviation, SNAP-25,
synaptosomal-associated protein of 25 kDa, VAMP, vesicle-associated membrane protein
aLogistic regression model of the estimated odds ratios of clinical dementia vs. non-dementia (i.e. NCI and MCI participants) per unit of regressor
bLinear regression model predicting global cognitive function nearest to death
cGlobal values
dValues obtained in the contralateral DLPFC by immunohistochemistry with specific antibodies
eEstimated as the mean value of calculated densities of the presynaptic proteins syntaxin-1, SNAP-25 and VAMP in the same brain samples
fValues normalized by β-actin
*Statistically significant P-value < 0.05
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dystrophic neurites and tangle-like structures. Notably,
the same results were observed for all 3 AD cases, while
none of the NCI subjects presented this anomalous dis-
tribution of FADD. As these results suggested a possible
role for FADD in the mechanisms of pathologic tau
deposition, DLPFC sections from subjects with AD were
used to study the possible colocalization of FADD with
pathological tau (Alz-50) and/or β-amyloid. The results
shown in Fig. 5b demonstrated the presence of FADD in
tangles and in dystrophic neurites where FADD coloca-
lized with Alz-50 immunoreactivity. FADD was also
present in the dystrophic neurites accumulating around
neuritic plaques (see Fig. 5b).
Decreased cortical FADD in APP23 mice with aging
Given the observed decrease in FADD content in MAP
participants with clinical dementia, and the potential asso-
ciation with common AD pathology, we utilized APP23
transgenic mice to further explore the possible role of
FADD in a common animal model of AD-like syndrome
(i.e., amyloid-β plaques accumulation with age). The re-
sults showed, in parallel to the human data, decreased
immunodensities of cortical FADD (normalized by β-actin
content) in APP23 mice as measured by a two-way
ANOVA (interaction Genotype x Age: F2,28 = 4.43, p =
0.021). Post-hoc multiple comparisons via t-tests revealed
significant decreases for adult (12 months old, p = 0.027)
and aged (22 months old, p = 0.030) APP23 mice as com-
pared to age-matched WTcontrols (Fig. 6).
Discussion
Pro-apoptotic FADD was lower in an elderly community-
based cohort of subjects with dementia, contrary to the
initial prediction of a higher level. Interestingly, lower
FADD in the DLPFC of MAP subjects was associated with
greater amyloid-β cortical accumulation, reduced synaptic
density, microglial activation, lower cognitive function, and
higher odds of dementia. In addition, subjects with AD de-
mentia presented an anomalous cortical FADD distribution
(i.e., presence in tangles and in dystrophic neurites),
compared to NCI subjects (i.e., FADD labeling in neur-
onal bodies). The redistribution of this adaptor protein into
cellular compartments where phosphotau accumulates
during the progression of AD may suggest a possible role
for FADD in the mechanisms of pathologic tau deposition.
Finally, in a common animal model of AD (i.e., APP23
mice), cortical FADD was also decreased, indicating that
FADD loss may be caused by age-related amyloid path-
ology, and suggesting that this multifunctional molecule
might be a key component in the amyloid cascade.
Cell death signals mediated by the extrinsic apoptotic
pathway are initiated through the interaction of Fas
receptor with FADD adaptor, which promotes activation
of effector caspases and leads to cell death [22, 62–64].
By contrast, when FADD is phosphorylated and translo-
cated to the nucleus, it mediates anti-apoptotic actions
[23, 59]. Thus FADD is a molecule key in controlling
cell-fate as it has demonstrated great plasticity in its
actions (see [60]). Interestingly, this study found marked
reductions in FADD (i.e., pro-apoptotic form), but not
p-FADD (i.e., anti-apoptotic form), in the DLPFC of
MAP participants displaying clinical dementia and/or a
large burden of AD pathology. Similar results were ob-
served in a preliminary postmortem study performed in
an independent small subset of patients with AD (n = 5)
in which cortical (BA9) FADD was decreased (by about
Fig. 4 Cognitive decline trajectories of MAP participants ranked by cortical FADD levels. Global cognitive function was evaluated annually after
enrolment, for 5.6 years in average (range 3–12 years), and the scores were standardized as described in Methods. Participants were then aligned
longitudinally by the last cognitive test before death. Participants were divided into groups according to their tertile of FADD cortical expression
levels. The spaghetti plot on the left represents individual cognitive trajectories across the study. The panel on the right represents individual
annual scores (points), with the best fit (solid line) and the 95% confidence interval (shaded area) of the cognitive trajectories for each
FADD-ranked group overlapped
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Fig. 5 Immunofluorecence characterization of FADD in the DLPFC of neuropathology-free NCI (n = 3) and Alzheimer’s diseased (AD; n = 3; two
different subjects shown) MAP participants. Single-channel (in greys) or merged (in RGB) confocal images correspond to triple co-immunolabeled
sections with antibodies against FADD (H181, Santa-Cruz, 1:50) combined with either (a) synatxin-1 (STX1, clone SP7, locally produced, 1:1000)
and NeuN (Chemicon, clone A60, 1:250), or (b) beta-amyloid (Aβ, clone 6 F/3D, Dako, 1:100) and misfolded, pathologic tau (clone Alz-50, locally
produced, 1:500). In merged images, colors were arbitrarily assigned (as indicated at the top) to maximize overlap visualization. Overlap panels on
the right are ImageJ-generated bitmaps highlighting those pixels where significant colocalization over an unbiased threshold of intensities between
the indicated channels were detected in the corresponding pairwise colocalization analyses. Note the change in FADD localization in NCI (mainly in
neuronal nuclei and soma, and also some neuropil staining) compared to AD (redistributed to dystrophic neurites, tangles, and within amyloid
plaques) brains. Scale bars: 30 μm
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69%), while p-FADD was unaltered when compared to
matched controls (n = 4) [65]. In contrast, basal fore-
brain cholinergic neurons in AD brains expressed high
levels of FADD but at the same time did not contain
fragmented DNA, a cellular marker of apoptosis [30]. The
present results suggest that at the time of death, there
were no signs of pro-apoptotic activation mediated by
FADD, but a decrease in its content. A possible explan-
ation for FADD decrease could be that initial FADD trans-
location out of the nucleus (possibly towards the neurites)
could have started apoptotic cascades leading to cell
death. This massive death of cortical neurons could have
further explained the loss of FADD in these subjects. In
fact, beyond the amyloid hypothesis biological cascade,
the literature suggests a distinct timeline for the increase
in biomarker expression (i.e., amyloid β deposits, and
hyperphosphorylation of tau) leading to cell death, and
the start-point of cognitive decline that culminates in clin-
ical dementia [2]. Another possible explanation would
favor the neuroplastic actions of this multifunctional pro-
tein suggesting an adaptive response to a prior insult.
Interestingly, cognitive decline during aging is due not
only to neuronal loss, but is the result of functional
changes occurring over time (reviewed in [4]), including
synaptic dysfunction (or dysplasticity). According to this
model, FADD levels correlate positively with synaptic
density markers, such as the SNARE proteins, and nega-
tively with microglia activation, which is thought to be re-
sponsible for greater synaptic pruning in AD [66].
Following linear and logistic regression models controlled
for multiple confounders, lower FADD levels were associ-
ated with increased likelihood of clinical dementia and re-
duced global cognitive function, partially mediating the
effects of amyloid-β accumulation, but not those of phos-
photau deposition. Interestingly, these FADD-amyloid-β
mediation effects were observed in models where the out-
come was clinical dementia (which compared NCI/MCI
versus dementia subjects), but not in those predicting cog-
nitive function. Perhaps, this type of interaction between
FADD and amyloid-β may play a role in the transition
from non-dementia (either NCI or MCI) to dementia.
Immunofluorescence assays were performed to
characterize FADD at the cellular and anatomical levels,
and to evaluate possible changes in FADD expression
patterns in subjects with clinical dementia as compared
to NCI controls. Prior studies have suggested that FADD
is expressed in human neurons [67, 68] as well as in
neuron-enriched cultures from human brain cortex [60].
Other studies have also suggested that FADD is expressed
in glial cells (e.g., glioblastoma cell lines; [69]). At the
subcellular level, FADD forms are expressed (rodent and
human brains) in cytosol and nucleus and to a lesser
extent in membranes (e.g., [58]; see revision in [60]). In line
with this, the present results showed that NCI subjects ac-
cumulated most FADD intensity in the neuronal cell body,
especially within nuclei. In contrast, subjects with clinical
dementia presented an anomalous FADD distribution, with
FADD presence in tangles and in dystrophic neurites, rep-
resented by the colocalization observed between FADD and
pathological tau (i.e., Alz-50 immunoreacctivity). A report
of increased FADD in AD (i.e., within the basal forebrain
cholinergic neurons), demonstrated FADD colocalized with
phosphorylated tau immunoreactive tangles but not with
dense-core amyloid β plaques [30]. These results, in line
with ours, suggest a possible role for FADD in the mecha-
nisms of pathologic tau deposition.
Previous observations in transgenic mouse models sug-
gested that cerebral amyloidosis in APP23 mice caused a
Fig. 6 Decreased cortical FADD in APP23 mice with aging. a
Immunodensity of FADD protein (normalized by β-actin protein
content) were quantified by Western blotting in cortical homogenates
from APP23 transgenic and wild-type (WT) mice at 3, 12 and 22 months
of age. Group of treatment: WT-3 months (n = 6), APP23-3 months
(n = 6), WT-12 months (n = 6), APP23-12 months (n = 5), WT-22 months
(n = 6), APP23-22 months (n = 5). Columns represent mean values ±
SEM per group and expressed as percentage of an in-gel standard.
Two-way ANOVA detected an interaction Genotype x Age (F2,28 = 4.43,
p < 0.05). Post-hoc multiple comparison t-tests revealed significant
decreases for adult (12 months old) and aged (22 months old) APP23
mice as compared to age-matched WT controls. *p < 0.05. b
Representative immunoblots of FADD and β-actin, with one sample
per group and age. The molecular masses of the various proteins are
indicated in kDa. Full gel images are included in Additional file 2:
Figure S2
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modest neuronal loss in neocortex at early ages, followed
by more neurons with necrotic-apoptotic phenotype in
the neocortex at 24 months of age [70]. However, to the
best of our knowledge no prior reports evaluated the regu-
lation of apoptotic markers (i.e., FADD) in APP23 mice.
In the present study, aged APP23 mice displayed reduced
levels of cortical FADD, suggesting FADD loss may be
dependent on age-related amyloid pathology. Interestingly,
cognitive decline in AD seems to correlate better with
neurofibrillary tangles of hyperphosphorylated tau than
with amyloid β plaques (see review in [4]). Interestingly,
the present results suggest a functional interaction be-
tween FADD and pathological tau, but at the same time
shows that FADD is sensitive to the accumulation of
amyloid β. Therefore, it is reasonable to speculate that
FADD might participate in the process of connecting
these two classical pathological markers in the progress of
clinical dementia, opening room for further studies.
Conclusions
The present results demonstrate that cortical FADD was de-
creased in an elderly, community-based cohort subjects with
dementia. Interestingly, loss of FADD in the DLPFC was
associated with a greater load of amyloid pathology, loss of
presynaptic terminal markers, poorer cognitive function and
increased risk of dementia. Moreover, subjects with AD
presented an anomalous cortical FADD distribution, (i.e.,
presence in tangles and in dystrophic neurites) as compared
to NCI subjects (i.e., FADD labeling in neuronal bodies) sug-
gesting a possible role for FADD in the mechanisms of
pathologic tau deposition. Moreover, the decrease in
FADD content was consistent with findings in a trans-
genic mouse model of AD. Overall, the present data
suggests FADD as a putative biomarker of the cognitive
decline associated with the course of clinical dementia.
Future studies should investigate the precise role of this
multifunctional adaptor protein within the amyloid cas-
cade, possibly linking plaque-mediated synaptotoxicity
and tauopathy in AD.
Additional files
Additional file 1: Figure S1. Colocalization of FADD and HLA-DR
positive (activated) microglia in the DLPFC of neuropathology-free NCI
(n = 3) MAP participants. Single-channel (in greys) or merged confocal
images correspond to double co-immunolabeled sections with antibodies
against FADD (H181, Santa-Cruz, 1:50; magenta) and HLA-DR (clone CR3/43,
Dako, 1:100; green). In merged image, colors were arbitrarily assigned to
maximize overlap visualization. Overlap panel is an ImageJ-generated
bitmap highlighting those pixels where significant colocalization over an
unbiased threshold of intensities between the indicated channels was
detected in pairwise colocalization analyses. Unlike its neuronal localization
pattern, FADD seems absent from the microglial nuclei, and mayor
colocalization between these markers appears in activated microglial processes
(see yellow arrows). Possibly, FADD microglial inclusions might derive from
post-apoptotic neurons. Scale bar: 20 μm. (PDF 292 kb)
Additional file 2: Figure S2. (a) Representative full gel immunoblots of
FADD, p-FADD and ß-actin proteins in the DLPFC of MAP participants, with
various participants and standard (ST) samples. The red square represents
the portion selected for Fig. 3d. (b) Representative full gel immunoblots of
FADD and ß-actin proteins in cortical homogenates from APP23
transgenic mice. The red square represents the portion selected for
Fig. 5b. The apparent molecular masses of the various proteins were
determined by calibrating the blots with prestained molecular weight
markers as shown on the left-hand side. (PDF 2893 kb)
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